JAMA Oncol:nab-紫杉醇新辅助化疗加用地诺单抗对原发性乳腺癌病理完全缓解率的影响

2022-05-24 MedSci原创 MedSci原创

在基于蒽环类/紫杉烷的新辅助化疗方案中加用地诺单抗并不能提高原发性乳腺癌患者的病理完全缓解率。

地诺单抗(Denosumab,又称AMC-162,商品名Prolia)是一种有独特作用机制的骨吸收抑制剂,通过特异性靶向核因子κB受体活化因子配体抑制破骨细胞活化,从而减少骨吸收,增加骨密度。地诺单抗辅助治疗可能会延长激素受体 (HR) 阳性原发性乳腺癌 (BC) 的无病生存期。但目前地诺单抗与白蛋白结合型紫杉醇联合辅助化疗的最佳方案尚不明确。

GeparX研究是一项多中心、前瞻性、开放标签、2b期、2×2的随机临床试验,目的是明确在含蒽环类/紫杉醇的新辅助化疗(NACT)方案中加用地诺单抗是否可提高乳腺癌患者的病理缓解率(pCR),以及哪种白蛋白结合型紫杉醇方案在 NACT 环境中更有效。


研究流程

从德国的38个地点招募了单侧或双侧、cT2-cT4a-d或cT1c期原发性乳腺癌患者,随机分成两组,予以或不予以地诺单抗(120mg/4周,皮下,共6剂)+白蛋白结合型紫杉醇(125mg/m2·周×12周或第1和8天/3周×4个疗程),继以表柔比星/环磷酰胺(90/600mg/m2·2周/3周×4个疗程)。主要终点是病理完全缓解率。


根据地诺单抗分组的病理完全缓解率

2017年2月至2019年3月,共筛查了1017位乳腺癌患者(包括男性患者),其中780位(包括1位男性患者)被随机分至地诺单抗组或非地诺单抗组(各390位,入组时的中位年龄 49.0岁)。地诺单抗组和非地诺单抗组的病理完全缓解(ypT0或ypN0)率分别是41.0%和42.8%(p=0.58),无论乳腺癌亚型如何。与白蛋白结合型紫杉醇三周疗程方案相比,每周疗程方案可显著提高患者的病理完全缓解率(44.9% vs 39.0%,p=0.06)。在亚组分析中,白蛋白结合型紫杉醇方案的病理完全缓解率仅在TNBC患者中存在显著差异(60.4% vs 50.0%,p=0.06)


根据紫杉醇方案分组的病理完全缓解率

无论有无加用地诺单抗,3-4级毒性反应的发生率没有明显差异。白蛋白结合型紫杉醇每周疗程方案的3-4级非血液学毒性反应率相对更高(33.7% vs 24.1%,p=0.004)。

综上,在基于蒽环类/紫杉烷的新辅助化疗方案中加用地诺单抗并不能提高原发性乳腺癌患者的病理完全缓解率。与白蛋白结合型紫杉醇3周疗程方案相比,每周疗法方案可显著提高病理完全缓解率,但会导致更高的毒性。

 

原始出处:

Blohmer J, Link T, Reinisch M, et al. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2?×?2 Randomized Clinical Trial. JAMA Oncol. Published online May 19, 2022. doi:10.1001/jamaoncol.2022.1059.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642484, encodeId=2135164248460, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Sun Feb 26 19:44:37 CST 2023, time=2023-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Tue Apr 11 16:44:37 CST 2023, time=2023-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799685, encodeId=0ab81e9968529, content=<a href='/topic/show?id=872ee102683' target=_blank style='color:#2F92EE;'>#病理完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71026, encryptionId=872ee102683, topicName=病理完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jan 21 15:44:37 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866613, encodeId=448b186661363, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 02 06:44:37 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847049, encodeId=4422184e04990, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 01 02:44:37 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243516, encodeId=303c124351692, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue May 24 02:44:37 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1642484, encodeId=2135164248460, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Sun Feb 26 19:44:37 CST 2023, time=2023-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Tue Apr 11 16:44:37 CST 2023, time=2023-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799685, encodeId=0ab81e9968529, content=<a href='/topic/show?id=872ee102683' target=_blank style='color:#2F92EE;'>#病理完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71026, encryptionId=872ee102683, topicName=病理完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jan 21 15:44:37 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866613, encodeId=448b186661363, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 02 06:44:37 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847049, encodeId=4422184e04990, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 01 02:44:37 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243516, encodeId=303c124351692, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue May 24 02:44:37 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1642484, encodeId=2135164248460, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Sun Feb 26 19:44:37 CST 2023, time=2023-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Tue Apr 11 16:44:37 CST 2023, time=2023-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799685, encodeId=0ab81e9968529, content=<a href='/topic/show?id=872ee102683' target=_blank style='color:#2F92EE;'>#病理完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71026, encryptionId=872ee102683, topicName=病理完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jan 21 15:44:37 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866613, encodeId=448b186661363, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 02 06:44:37 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847049, encodeId=4422184e04990, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 01 02:44:37 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243516, encodeId=303c124351692, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue May 24 02:44:37 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1642484, encodeId=2135164248460, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Sun Feb 26 19:44:37 CST 2023, time=2023-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Tue Apr 11 16:44:37 CST 2023, time=2023-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799685, encodeId=0ab81e9968529, content=<a href='/topic/show?id=872ee102683' target=_blank style='color:#2F92EE;'>#病理完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71026, encryptionId=872ee102683, topicName=病理完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jan 21 15:44:37 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866613, encodeId=448b186661363, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 02 06:44:37 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847049, encodeId=4422184e04990, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 01 02:44:37 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243516, encodeId=303c124351692, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue May 24 02:44:37 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2023-03-02 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=1642484, encodeId=2135164248460, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Sun Feb 26 19:44:37 CST 2023, time=2023-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Tue Apr 11 16:44:37 CST 2023, time=2023-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799685, encodeId=0ab81e9968529, content=<a href='/topic/show?id=872ee102683' target=_blank style='color:#2F92EE;'>#病理完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71026, encryptionId=872ee102683, topicName=病理完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jan 21 15:44:37 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866613, encodeId=448b186661363, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 02 06:44:37 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847049, encodeId=4422184e04990, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 01 02:44:37 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243516, encodeId=303c124351692, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue May 24 02:44:37 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1642484, encodeId=2135164248460, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Sun Feb 26 19:44:37 CST 2023, time=2023-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678747, encodeId=0dae16e8747fc, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Tue Apr 11 16:44:37 CST 2023, time=2023-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799685, encodeId=0ab81e9968529, content=<a href='/topic/show?id=872ee102683' target=_blank style='color:#2F92EE;'>#病理完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71026, encryptionId=872ee102683, topicName=病理完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jan 21 15:44:37 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866613, encodeId=448b186661363, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 02 06:44:37 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847049, encodeId=4422184e04990, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 01 02:44:37 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243516, encodeId=303c124351692, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Tue May 24 02:44:37 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-05-24 肿瘤克星

    JAMA上文章都是顶级的,谢谢梅斯及时上新

    0

相关资讯

Lancet Gastroen Heptaol:胃癌二线化疗,白蛋白结合型紫杉醇vs溶剂型紫杉醇

每周使用溶剂型紫杉醇是晚期胃癌的二线化疗方案之一。白蛋白结合型紫杉醇纳米粒(nab-paclitaxel)的开发是为了提高紫杉醇的溶解度且不必术前用药进而避免了与溶剂型紫杉醇相关的输液反应。此外,与溶剂型紫杉醇相比,高剂量的白蛋白结合型紫杉醇可以通过更短的输液时间达到较高的药物浓度。但具体效果如何?最新一期的The Lancet Gastroenterology & Heptaology在

ASCO 2012:白蛋白结合型紫杉醇治疗多种肿瘤显优势

      与其他剂型紫杉醇相比,新型靶向化疗药物白蛋白结合型紫杉醇(nab-P,Abraxane)可在肿瘤局部产生更高的紫杉醇浓度,且注射时间短。Nab-P可通过gp60穿胞途径及结合于肿瘤细胞外间质的富含半胱氨酸的酸性分泌蛋白(SPARC)途径来提高肿瘤外药物浓度。目前,该药已获美国食品与药物管理局(FDA)批准用于辅助化疗6个月内转移或复发,经联合化疗无效的乳腺

Eur J Cancer:吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性

吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效相当